These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 24927689)

  • 1. Serum levels of sclerostin, Dickkopf-1, and secreted frizzled-related protein-4 are not changed in individuals with high bone mass causing mutations in LRP5.
    Simpson CA; Foer D; Lee GS; Bihuniak J; Sun B; Sullivan R; Belsky J; Insogna KL
    Osteoporos Int; 2014 Oct; 25(10):2383-8. PubMed ID: 24927689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Bone Mass-Causing Mutant LRP5 Receptors Are Resistant to Endogenous Inhibitors In Vivo.
    Niziolek PJ; MacDonald BT; Kedlaya R; Zhang M; Bellido T; He X; Warman ML; Robling AG
    J Bone Miner Res; 2015 Oct; 30(10):1822-30. PubMed ID: 25808845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum extracellular secreted antagonists of the canonical Wnt/β-catenin signaling pathway in patients with Cushing's syndrome.
    Belaya ZE; Rozhinskaya LY; Melnichenko GA; Solodovnikov AG; Dragunova NV; Iljin AV; Dzeranova LK; Dedov II
    Osteoporos Int; 2013 Aug; 24(8):2191-9. PubMed ID: 23358608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of blood bone turnover biomarkers and Wnt signaling antagonists with AS, DISH, OPLL, and OYL.
    Niu CC; Lin SS; Yuan LJ; Chen LH; Yang CY; Chung AN; Lu ML; Tsai TT; Lai PL; Chen WJ
    BMC Musculoskelet Disord; 2017 Feb; 18(1):61. PubMed ID: 28153008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis.
    Taylan A; Sari I; Akinci B; Bilge S; Kozaci D; Akar S; Colak A; Yalcin H; Gunay N; Akkoc N
    BMC Musculoskelet Disord; 2012 Oct; 13():191. PubMed ID: 23025387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Wnt/β-catenin and RANKL/OPG in bone healing of diabetic Charcot arthropathy patients.
    Folestad A; Ålund M; Asteberg S; Fowelin J; Aurell Y; Göthlin J; Cassuto J
    Acta Orthop; 2015; 86(4):415-25. PubMed ID: 25811776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of gain-of-function mutations in the low-density lipoprotein receptor-related protein 5 (LRP5) on glucose and lipid homeostasis.
    Foer D; Zhu M; Cardone RL; Simpson C; Sullivan R; Nemiroff S; Lee G; Kibbey RG; Petersen KF; Insogna KL
    Osteoporos Int; 2017 Jun; 28(6):2011-2017. PubMed ID: 28283687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity.
    Ellies DL; Viviano B; McCarthy J; Rey JP; Itasaki N; Saunders S; Krumlauf R
    J Bone Miner Res; 2006 Nov; 21(11):1738-49. PubMed ID: 17002572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated circulating Sclerostin concentrations in individuals with high bone mass, with and without LRP5 mutations.
    Gregson CL; Poole KE; McCloskey EV; Duncan EL; Rittweger J; Fraser WD; Smith GD; Tobias JH
    J Clin Endocrinol Metab; 2014 Aug; 99(8):2897-907. PubMed ID: 24606091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of plasma, serum, and platelet serotonin in individuals with high bone mass and mutations in LRP5.
    Lee GS; Simpson C; Sun BH; Yao C; Foer D; Sullivan B; Matthes S; Alenina N; Belsky J; Bader M; Insogna KL
    J Bone Miner Res; 2014 Apr; 29(4):976-81. PubMed ID: 24038240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High bone density due to a mutation in LDL-receptor-related protein 5.
    Boyden LM; Mao J; Belsky J; Mitzner L; Farhi A; Mitnick MA; Wu D; Insogna K; Lifton RP
    N Engl J Med; 2002 May; 346(20):1513-21. PubMed ID: 12015390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis.
    Brabnikova-Maresova K; Jarosova K; Pavelka K; Stepan JJ
    Arthritis Res Ther; 2014 Oct; 16(5):460. PubMed ID: 25280749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New explanation for autosomal dominant high bone mass: Mutation of low-density lipoprotein receptor-related protein 6.
    Whyte MP; McAlister WH; Zhang F; Bijanki VN; Nenninger A; Gottesman GS; Lin EL; Huskey M; Duan S; Dahir K; Mumm S
    Bone; 2019 Oct; 127():228-243. PubMed ID: 31085352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel LRP5 missense mutation in a patient with a high bone mass phenotype results in decreased DKK1-mediated inhibition of Wnt signaling.
    Balemans W; Devogelaer JP; Cleiren E; Piters E; Caussin E; Van Hul W
    J Bone Miner Res; 2007 May; 22(5):708-16. PubMed ID: 17295608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The key role of proinflammatory cytokines, matrix proteins, RANKL/OPG and Wnt/β-catenin in bone healing of hip arthroplasty patients.
    Cassuto J; Folestad A; Göthlin J; Malchau H; Kärrholm J
    Bone; 2018 Feb; 107():66-77. PubMed ID: 29129760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating levels of dickkopf-1, osteoprotegerin and sclerostin are higher in old compared with young men and women and positively associated with whole-body bone mineral density in older adults.
    Coulson J; Bagley L; Barnouin Y; Bradburn S; Butler-Browne G; Gapeyeva H; Hogrel JY; Maden-Wilkinson T; Maier AB; Meskers C; Murgatroyd C; Narici M; Pääsuke M; Sassano L; Sipilä S; Al-Shanti N; Stenroth L; Jones DA; McPhee JS
    Osteoporos Int; 2017 Sep; 28(9):2683-2689. PubMed ID: 28585053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenic mutations and polymorphisms in the lipoprotein receptor-related protein 5 reveal a new biological pathway for the control of bone mass.
    Ferrari SL; Deutsch S; Antonarakis SE
    Curr Opin Lipidol; 2005 Apr; 16(2):207-14. PubMed ID: 15767861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.
    Anastasilakis AD; Polyzos SA; Gkiomisi A; Bisbinas I; Gerou S; Makras P
    J Clin Endocrinol Metab; 2013 Aug; 98(8):3206-12. PubMed ID: 23788684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer.
    Kyvernitakis I; Rachner TD; Urbschat A; Hars O; Hofbauer LC; Hadji P
    J Cancer Res Clin Oncol; 2014 Oct; 140(10):1671-80. PubMed ID: 24903965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of the bone turnover markers dickkopf-1, sclerostin, osteoprotegerin, osteopontin, osteocalcin and 25-hydroxyvitamin D in Swedish geriatric patients aged 75 years or older with a fresh hip fracture and in healthy controls.
    Wanby P; Nobin R; Von SP; Brudin L; Carlsson M
    J Endocrinol Invest; 2016 Aug; 39(8):855-63. PubMed ID: 26850415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.